Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs COF: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at COF's multiple
Needs COF P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · COF FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
CAPITAL ONE FINANCIAL CORP · implied price per share
Bear
$406.27
Base
$477.97
Bull
$549.66
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.45x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
-0.50x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$66.64B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
JPMorgan Chase & Co.
HRMY vs JPM
Bank of America Corporation
HRMY vs BAC
Wells Fargo & Company
HRMY vs WFC
Citigroup Inc.
HRMY vs C
$163.66M
$51.00B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY can sustain its 21.5% revenue growth while preserving its 77.2% gross margin and 18.3% net margin, then the stock looks attractive versus the P/E-based implied value because the current price is far below $137.96 and the balance sheet remains net-cash positive.
HRMY trades at $37.26 versus a P/E-implied price of $137.96, implying 270.3% upside on that framework. However, COF-implied range is very wide at $35.84 to $139.54, and HRMY already sits inside its historical band and DCF range, which suggests the valuation opportunity is real but not uniformly supported across methods.
Supporting Metrics
Live quote
